CML: MOLECULAR ONCOLOGY TUMOR BOARDS COURSE REFERENCES

Transcription

1 CML: MOLECULAR ONCOLOGY TUMOR BOARDS COURSE REFERENCES Abruzzese, E., Trawinska, M. M., de Fabritiis, P., & Baccarani, M. (2016). Management of pregnant chronic myeloid leukemia patients. Expert Rev Hematol, 9(8), doi: / Aichberger, K. J., Herndlhofer, S., Schernthaner, G. H., Schillinger, M., Mitterbauer-Hohendanner, G., Sillaber, C., & Valent, P. (2011). Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol, 86(7), doi: /ajh Alhawiti, N., Burbury, K. L., Kwa, F. A., O'Malley, C. J., Shuttleworth, P., Alzard, M.,... Jackson, D. E. (2016). The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state. Thromb Res, 145, doi: /j.thromres Brixey, A. G., & Light, R. W. (2010). Pleural effusions due to dasatinib. Curr Opin Pulm Med, 16(4), doi: /mcp.0b013e328338c486 Coburn, A. M., Cappon, G. D., Bowman, C. J., Stedman, D. B., & Patyna, S. (2012). Reproductive toxicity assessment of sunitinib, a multitargeted receptor tyrosine kinase inhibitor, in male and female rats. Birth Defects Res B Dev Reprod Toxicol, 95(4), doi: /bdrb Cortes, J., Kim, D. W., Raffoux, E., Martinelli, G., Ritchie, E., Roy, L.,... Talpaz, M. (2008). Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia, 22(12), doi: /leu Cortes, J., Rousselot, P., Kim, D. W., Ritchie, E., Hamerschlak, N., Coutre, S.,... Baccarani, M. (2007). Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood, 109(8), doi: /blood Cortes, J. E., Abruzzese, E., Chelysheva, E., Guha, M., Wallis, N., & Apperley, J. F. (2015). The impact of dasatinib on pregnancy outcomes. Am J Hematol, 90(12), doi: /ajh Cortes, J. E., Kim, D. W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C.,... Investigators, P. (2013). A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med, 369(19), doi: /nejmoa Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N.,... Investigators, I. (2006). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, 355(23), doi: /nejmoa Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M.,... Sawyers, C. L. (2001). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med, 344(14), doi: /nejm

2 Egorin, M. J., Shah, D. D., Christner, S. M., Yerk, M. A., Komazec, K. A., Appleman, L. R.,... Beumer, J. H. (2009). Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. Br J Clin Pharmacol, 68(3), doi: /j x Fabarius, A., Leitner, A., Hochhaus, A., Muller, M. C., Hanfstein, B., Haferlach, C.,... the German, C. M. L. S. G. (2011). Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood, 118(26), doi: /blood Feldman, E., Najfeld, V., Schuster, M., Roboz, G., Chadburn, A., & Silver, R. T. (2003). The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Exp Hematol, 31(8), Fossard, G., Blond, E., Balsat, M., Morisset, S., Giraudier, S., Escoffre-Barbe, M.,... Nicolini, F. E. (2016). Hyperhomocysteinemia and high doses of nilotinib favor cardiovascular events in chronic phase Chronic Myelogenous Leukemia patients. Haematologica, 101(3), e doi: /haematol Giles, F. J., Mauro, M. J., Hong, F., Ortmann, C. E., McNeill, C., Woodman, R. C.,... Saglio, G. (2013). Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia, 27(6), doi: /leu Gora-Tybor, J., Medras, E., Calbecka, M., Kolkowska-Lesniak, A., Ponikowska-Szyba, E., Robak, T., & Jamroziak, K. (2015). Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment. Leuk Lymphoma, 56(8), doi: / Gugliotta, G., Castagnetti, F., Breccia, M., Levato, L., D'Adda, M., Stagno, F.,... Party, G. C. W. (2015). Longterm outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia. Haematologica, 100(9), doi: /haematol Hjorth-Hansen, H., Stenke, L., Soderlund, S., Dreimane, A., Ehrencrona, H., Gedde-Dahl, T.,... Nordic, C. M. L. S. G. (2015). Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006). Eur J Haematol, 94(3), doi: /ejh Hochhaus, A., Saglio, G., Hughes, T. P., Larson, R. A., Kim, D. W., Issaragrisil, S.,... Kantarjian, H. M. (2016). Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia, 30(5), doi: /leu Holzerova, M., Faber, E., Veselovska, J., Urbankova, H., Balcarkova, J., Rozmanova, S.,... Project, C. A.-C. M. L. (2009). Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: single-center results. Cancer Genet Cytogenet, 191(1), 1-9. doi: /j.cancergencyto Jabbour, E., Kantarjian, H. M., Saglio, G., Steegmann, J. L., Shah, N. P., Boque, C.,... Hochhaus, A. (2014). Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood, 123(4), doi: /blood Jain, P., Kantarjian, H., Sasaki, K., Jabbour, E., Dasarathula, J., Nogueras Gonzalez, G.,... Cortes, J. (2016). Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. Br J Haematol, 173(1), doi: /bjh

3 Kantarjian, H. M., Hochhaus, A., Saglio, G., De Souza, C., Flinn, I. W., Stenke, L.,... Hughes, T. P. (2011). Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol, 12(9), doi: /s (11) Kantarjian, H. M., Shah, N. P., Cortes, J. E., Baccarani, M., Agarwal, M. B., Undurraga, M. S.,... Hochhaus, A. (2012). Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood, 119(5), doi: /blood Khoury, H. J., Cortes, J. E., Kantarjian, H. M., Gambacorti-Passerini, C., Baccarani, M., Kim, D. W.,... Brummendorf, T. H. (2012). Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood, 119(15), doi: /blood Kim, T. D., Rea, D., Schwarz, M., Grille, P., Nicolini, F. E., Rosti, G.,... le Coutre, P. D. (2013). Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia, 27(6), doi: /leu Larson, R. A., Hochhaus, A., Hughes, T. P., Clark, R. E., Etienne, G., Kim, D. W.,... Kantarjian, H. M. (2012). Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia, 26(10), doi: /leu Mahon, F. X., Rea, D., Guilhot, J., Guilhot, F., Huguet, F., Nicolini, F.,... Intergroupe Francais des Leucemies Myeloides, C. (2010). Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol, 11(11), doi: /s (10) Medina, J., Kantarjian, H., Talpaz, M., O'Brien, S., Garcia-Manero, G., Giles, F.,... Cortes, J. (2003). Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer, 98(9), doi: /cncr Moslehi, J. J., & Deininger, M. (2015). Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. J Clin Oncol, 33(35), doi: /jco Nurmio, M., Kallio, J., Toppari, J., & Jahnukainen, K. (2008). Adult reproductive functions after early postnatal inhibition by imatinib of the two receptor tyrosine kinases, c-kit and PDGFR, in the rat testis. Reprod Toxicol, 25(4), doi: /j.reprotox O'Sullivan, S., Lin, J. M., Watson, M., Callon, K., Tong, P. C., Naot, D.,... Grey, A. (2011). The skeletal effects of the tyrosine kinase inhibitor nilotinib. Bone, 49(2), doi: /j.bone Palani, R., Milojkovic, D., & Apperley, J. F. (2015). Managing pregnancy in chronic myeloid leukaemia. Ann Hematol, 94 Suppl 2, S doi: /s z Quintas-Cardama, A., Kantarjian, H., O'Brien, S., Borthakur, G., Bruzzi, J., Munden, R., & Cortes, J. (2007). Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol, 25(25), doi: /jco Roboz, G. J., Bennett, J. M., Coleman, M., Ritchie, E. K., Furman, R. R., Rossi, A.,... Leonard, J. P. (2007). Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-hodgkin lymphoma. Leuk Res, 31(8), doi: /j.leukres

4 Ross, D. M., Branford, S., Seymour, J. F., Schwarer, A. P., Arthur, C., Yeung, D. T.,... Hughes, T. P. (2013). Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood, 122(4), doi: /blood Rosti, G., Palandri, F., Castagnetti, F., Breccia, M., Levato, L., Gugliotta, G.,... Party, G. C. W. (2009). Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood, 114(24), doi: /blood Rousselot, P., Cony-Makhoul, P., Nicolini, F., Mahon, F. X., Berthou, C., Rea, D.,... French Intergroup For Chronic Myelogenous, L. (2013). Long-term safety and efficacy of imatinib mesylate (Gleevec(R)) in elderly patients with chronic phase chronic myelogenous leukemia: results of the AFR04 study. Am J Hematol, 88(1), 1-4. doi: /ajh Rousselot, P., Huguet, F., Rea, D., Legros, L., Cayuela, J. M., Maarek, O.,... Mahon, F. X. (2007). Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood, 109(1), doi: /blood Saglio, G., Kim, D. W., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C.,... Investigators, E. N. (2010). Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med, 362(24), doi: /nejmoa Sasaki, K., Strom, S. S., O'Brien, S., Jabbour, E., Ravandi, F., Konopleva, M.,... Cortes, J. E. (2015). Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol, 2(5), e doi: /s (15) Shah, N. P., Guilhot, F., Cortes, J. E., Schiffer, C. A., le Coutre, P., Brummendorf, T. H.,... Saglio, G. (2014). Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood, 123(15), doi: /blood Terre, C., Eclache, V., Rousselot, P., Imbert, M., Charrin, C., Gervais, C.,... France Intergroupe pour la Leucemie Myeloide, C. (2004). Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia, 18(8), doi: /sj.leu Thielen, N., van der Holt, B., Cornelissen, J. J., Verhoef, G. E., Gussinklo, T., Biemond, B. J.,... Janssen, J. J. (2013). Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON). Eur J Cancer, 49(15), doi: /j.ejca Valent, P., Hadzijusufovic, E., Schernthaner, G. H., Wolf, D., Rea, D., & le Coutre, P. (2015). Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood, 125(6), doi: /blood Wang, W., Chen, Z., Hu, Z., Yin, C. C., Li, S., Bai, S.,... Hu, S. (2016). Clinical significance of trisomy 8 that emerges during therapy in chronic myeloid leukemia. Blood Cancer J, 6(11), e490. doi: /bcj Wang, W., Cortes, J. E., Tang, G., Khoury, J. D., Wang, S., Bueso-Ramos, C. E.,... Hu, S. (2016). Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood, 127(22), doi: /blood

5 5